Clinical Therapeutics  bioavailability of exenatide (syn-  thetic exendin-4). ClinTker. 2005;27:  210-215.  16. Wallace TM, LevyJC, Matthews DR.  Use and abuse of HOMA modeling.  Diabetes Care. 2004;27:1487-1495.  17. DavisJE, McDonald JM, Jarett L. A  high-performance liquid chroma-  tography method for hemoglobin  Ale. Diabetes. 1978;27:102-107.  18. Cole IRA, Soeldner JS, Dunn PJ,  Bunn HF. A rapid method for the  determination of glycosylated he-  moglobins using high pressure liq-  uid chromatography. Metabolism.  1978;27:289-301.  19. Fineman MS, BicsakTA, Shen 17 et  al. Effect on glycemic control ofex-  enatide (synthetic exendin-4) addi-  tive to existing metformin and/or  sulfonylurea treatment in patients  with type 2 diabetes. Diabetes Care.  2003;26:2370-2377.  20. HayterAJ. The maximum famil~wise  error rate of Fisher's least signifi-  cant difference test. J Am Stat Assoc.  1986;81:1000-1004.  21. Kleinbaum DG, Kupper LL, eds. Ap-  plied Regression Analysis and Other